$0.68
12.06% yesterday
Nasdaq, Dec 23, 10:05 pm CET
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Tiziana Life Sciences PLC Sponsored ADR Stock price

$0.68
-0.28 29.00% 1M
-0.27 28.11% 6M
+0.12 21.70% YTD
+0.07 11.70% 1Y
-0.28 29.13% 3Y
-0.55 44.83% 5Y
-0.97 58.64% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
-0.09 12.06%
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Key metrics

Market capitalization $75.41m
Enterprise Value $57.66m
EV/FCF (TTM) EV/FCF negative
Short interest 0.32%

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

Buy
100%

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '22
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
64% 64%
-
-0.05 -0.05
64% 64%
-
- Selling and Administrative Expenses 4.71 4.71
70% 70%
-
- Research and Development Expense 13 13
2% 2%
-
-18 -18
39% 39%
-
- Depreciation and Amortization 0.05 0.05
64% 64%
-
EBIT (Operating Income) EBIT -18 -18
39% 39%
-
Net Profit -15 -15
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Positive
Proactive Investors
7 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company said this milestone took place at Brigham and Women's Hospital in Boston as part of a study aimed at addressing neuroinflammation, a key factor in Alzheimer's progression.
Positive
Proactive Investors
20 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional trial sites across the Northeast of the United States. The trial sites include highly-regarded institutions, including Yale University, Johns Hopkins University, Cornell University, Universi...
Positive
Proactive Investors
about one month ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Program which will be used for a 20-patient study investigating the safety and early efficacy of its investigational drug intranasal foralumab in patients with Amyotrophic Lateral Sclerosis (ALS), a pro...
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Ivor Elrifi
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today